Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analogue that binds to serum albumin in vivo and is approved for once-daily treatment of diabetes as well as obesity. The aim of the present studies was to design a once weekly GLP-1 analogue by increasing albumin affinity and secure full stability against metabolic degradation. The fatty acid moiety and the linking chemistry to GLP-1 were the key features to secure high albumin affinity and GLP-1 receptor (GLP-1R) potency and in obtaining a prolonged exposure and action of the GLP-1 analogue. Semaglutide was selected as the optimal once weekly candidate. Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib(8), Arg(34)) and is derivatized at lysine 26. The GLP-1R affinity of semaglutide (0.38 ± 0.06 nM) was three-fold decreased compared to liraglutide, whereas the albumin affinity was increased. The plasma half-life was 46.1 h in mini-pigs following i.v. administration, and semaglutide has an MRT of 63.6 h after s.c. dosing to mini-pigs. Semaglutide is currently in phase 3 clinical testing.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The elimination half-life of 7 (Table 2), as measured after i.v. dose in minipigs, could be increased by nearly 40% through the replacement of the C18 diacid protractor with a C20 diacid (8), providing an even more attractive PK profile for potential once-weekly clinical administration when compared to the once-weekly GLP-1R agonist semaglutide [47].”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [47]
In the citing paper
“We estimated the required sample size to be 60 participants (30 for oral and 30 for subcutaneous semaglutide), assuming a two-sided hypothesis test with a 95% confidence level and accounting for a potential 10% loss. This estimation was based on a minimum clinically relevant difference of -10% in fat body mass at the conclusion of the follow-up (22, 23).”
From Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus (2024) · cites this paper as [22]
In the citing paper
“Semaglutide, a GLP-1 analogue with an extended half-life of approximately 1 week (which permits once-weekly subcutaneous administration), 4”
From Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (2016) · cites this paper as [4]
In the citing paper
“The long half-life of semaglutide (approximately 7.5 hours in mice, 12 hours in rats, and 183 hours in humans) makes it suitable for once-weekly administration in humans (43, 48–50).”
From The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission (2023) · cites this paper as [48]
In the citing paper
“This formulation results in slower degradation and a half-life 155 to 184 hours, allowing for once-weekly subcutaneous dosing without compromising weight loss efficacy.(11, 26)”
From Semaglutide for the treatment of obesity (2023) · cites this paper as [26]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Schuck, P. (2000) · Biophysical Journal · doi:10.1016/s0006-3495(00)76713-0 · Cited by 3,868
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Kratz, F. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.010 · Cited by 2,151
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Fatty acid binding to plasma albumin
Spector, A. A. (1975) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)36723-7 · Cited by 966
Deacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 700
Self-citationAgersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510
Fatty acid binding to human serum albumin: new insights from crystallographic studies
Curry, S., Brick, P., & Franks, N. P. (1999) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(99)00148-1 · Cited by 495
Dungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrbach, J. L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60976-4 · Cited by 486
Research works printed but not linked: 1
- 10.1016/s0140-6736(09)60659-0 · DOI · Paper page
Cited by
Items 901–1,000 of 1,000
Yoo, K. H. (2026) · Aesthetic Surgery Journal · doi:10.1093/asj/sjag230 · Cited by 1
Niu, X., Nong, S., Zhang, X., Li, X., Wang, C., Li, W., & Zhou, T. (2020) · RSC Advances · doi:10.1039/d0ra00104j · Cited by 1
Major Classes of Biotherapeutics
Cruz, E., & Kayser, V. (2020) · Wiley eBooks · doi:10.1002/9781119564690.ch4 · Cited by 1
He, R., Mowery, S. A., Chabenne, J. R., Finan, B., Mayer, J. P., & DiMarchi, R. D. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.693958 · Cited by 1
“This GLP-1 agonist is a C18 diacid protracted GLP-1 analogue which allows once weekly dosing for the treatment of type 2 diabetes (2).”
BackgroundMethodGlucagon receptor family in GtoPdb v.2021.3
BATAILLE, D., Chan, S. L. F., Delagrange, P., Drucker, D. J., Göke, B., Hills, R., Mayo, K. E., Miller, L. J., Salvatori, R., & Thorens, B. (2021) · IUPHAR/BPS Guide to Pharmacology CITE · doi:10.2218/gtopdb/f29/2021.3 · Cited by 1
Development of RybelsusⓇ, the world’s first oral GLP-1 receptor agonist
Moriwaki, N., Akahori, M., & Sugii, H. (2022) · Drug Delivery System · doi:10.2745/dds.37.169 · Cited by 1
A Comprehensive Picture of Biotransformation in Drug Discovery
Cannon, J. R., Vachaspati, P. R., & Yuan, Y. (2022) · Wiley eBooks · doi:10.1002/9781119851042.ch4 · Cited by 1
Reality check: lipid-oligonucleotide conjugates for therapeutic applications
Goodnow, R. A. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2157399 · Cited by 2
“An illustrative example of using lipids to rationally modify the properties and bio-activity of a drug substance is the design of semaglutide, a glucagon-like peptide-1, in which the linker and lipid chemistry were optimized to enhance binding affinity of serum albumin, thereby prolonging its circulating exposure and…”
Efficacy of semaglutide: an evidence-based review
Mkrtumyan, A. M., & Egshatyan, L. V. (2022) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2022-010 · Cited by 2
Lubberding, A. F., Holst, J. J., & Madsbad, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00017-6 · Cited by 1
Purification and Activity Evaluation of a Novel Thrombopoietin Mimetic Peptide
Liang, Y., Li, Y., Ma, R., & Chuanren, D. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.11.020 · Cited by 1
Raval, H., & Sangave, P. C. (2024) · Current Nanomedicine · doi:10.2174/0124681873309964240521074809 · Cited by 3
Dombernowsky, S. L., Damholt, B. B., Rasmussen, M. H., Sværke, C., & Kildemoes, R. J. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01395-y · Cited by 1
“The prolonged action of somapacitan is achieved with a similar protraction technology that has previously been used successfully to extend the half-life of insulin [16] and glucagon-like peptide-1 therapies [17, 18].”
MethodO Uso da Semaglutida no Tratamento em Pacientes com Obesidade
da Silva, M. L., & da Silva, P. R. (2024) · Brazilian Journal of Biological Sciences · doi:10.21472/bjbs.v11n25-018 · Cited by 1
Evaluating semaglutide + LAI-287 (IcoSema) for the treatment of diabetes mellitus type II
Siamashvili, M., & Davis, S. N. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2436593 · Cited by 1
“Semaglutide (molecular formula: C 187 H 291 N 45 O 59 , molar mass: 4113.67 g·mol −1 ) is chemically similar to endogenous GLP-1 [17].”
InfluentialSelective Native N(in)–H Bond Activation in Peptides with Metallaphotocatalysis
Delgado, J. A. C., Amaral, J. C., Penteado, P. S., Ferreira, A. G., da Silva, M. F. D. G. F., König, B., & Paixão, M. W. (2025) · JACS Au · doi:10.1021/jacsau.5c00119 · Cited by 1
Advancements and challenges in the management of obesity using pharmacotherapy (Review)
Alotaibi, S. S., Eldrehmy, E. H., Albogami, S. M., Alkhedaide, A. Q., & Dahab, O. (2025) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2025.12912 · Cited by 1
“The half‑life of semaglutide ranges from 155 to 183 h (53) absorption and inhibit the breakdown of orally administered semaglutide in the stomach (54).”
Jörgensen, S. K. M., Surridge-Smith, M., Jones, K. M., Maletínská, L., Allen, N. D., & Petřík, D. (2025) · PLoS ONE · doi:10.1371/journal.pone.0329268 · Cited by 1
Semaglutide Exacerbates Stunting in Growth-Impaired Juvenile Male Mice via Reduced Energy Metabolism
Joly, A., Rebiffé, L., Dusabyinema, Y., Dellinger, J., Caillon, E., Gauthier, K. C., Leulier, F., & Vadder, F. D. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf158 · Cited by 2
The Design of a GLP‐1/PYY Dual Acting Agonist
Østergaard, S., Paulsson, J. F., Gerstenberg, M. K., & Wulff, B. S. (2021) · Angewandte Chemie · doi:10.1002/ange.202016464 · Cited by 4
Ritter, K. (2018) · Wiley eBooks · doi:10.1002/14356007.a03_001.pub3 · Cited by 2
A one-dimensional semaglutide-GLP-1R-based mini static GIBACPreprint
Li, W. (2024) · Preprints.org · doi:10.20944/preprints202406.0953.v1 · Cited by 1
Li, W. (2024) · Preprints.org · doi:10.20944/preprints202408.1713.v1 · Cited by 1
Weckbecker, C., Betz, K., Gerstmeir, R., Hartwig, B., Hess, V., Hoefer, N., Kottenhahn, P., Lersch, P., Loskyll, J., Oßwald, S., et al. (2026) · Ullmann's Encyclopedia of Industrial Chemistry · doi:10.1002/14356007.a02_057.pub3 · Cited by 1
Echeverría, C. E., Ahmed, M., Gao, J., Stewart, S. L., Nathoo, I., Debarba, L. K., Lafourcade, C., Ahmed, T., Shamieva, O., Perrier, T., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.03.729910 · Cited by 1
Blundell, J. E., Axelsen, M. B., Brooks, A., Flint, A., Kvist, T., Bergan, E. Q., & Hjerpsted, J. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(16)31220-7 · Cited by 1
Horigome, H., Inoue, A., Moriwaki, N., & Sugii, H. (2016) · Drug Delivery System · doi:10.2745/dds.31.423
Combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance
Ruyatkina, L. A., & Sorokin, M. (2016) · Diabetes Mellitus · doi:10.14341/7875
“Агонисты ГПП-1Р вводятся подкожно 1 или 2 раза в день (эксенатид, лираглутид, ликсисенатид) либо 1 раз в неделю (пролонгированная форма эксенатида, дулаглутид, албиглутид, семаглутид [16]).”
Herzinsuffizienz und Diabetes: Therapeutische Strategien unter Berücksichtigung aktueller Studien
Rau, M., & Lehrke, M. (2017) · Der Klinikarzt · doi:10.1055/s-0043-113349
Gallwitz, B. (2017) · Der Diabetologe · doi:10.1007/s11428-017-0266-y
Peptide Drug Design for Diabetes and Related Metabolic Diseases
Kaarsholm, N. C. (2019) · Springer eBooks · doi:10.1007/978-3-030-11748-1_13
Incretin Therapies: Current Use and Emerging Possibilities
Schlögl, H., & Stümvoll, M. (2019) · Springer eBooks · doi:10.1007/978-3-030-11815-0_33
Glucagon receptor family (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
BATAILLE, D., Chan, S. L. F., Delagrange, P., Drucker, D. J., Göke, B., Hills, R., Mayo, K. E., Miller, L. J., Salvatori, R., & Thorens, B. (2019) · IUPHAR/BPS Guide to Pharmacology CITE · doi:10.2218/gtopdb/f29/2019.4
A szemaglutid szerkezete és farmakológiája
Winkler, G. (2019) · Diabetologia Hungarica · doi:10.24121/dh.2019.s2.1
Focus on New Diabetes Treatment Options with Cardiovascular Benefits
Jun, J. K. (2019) · Journal of Contemporary Pharmacy Practice · doi:10.37901/jcphp18-00029
Development of CGRP receptor peptide antagonists as potential therapeutics
Jamaluddin, A. (2020) · University of Birmingham Research Portal (University of Birmingham)
Morales-Villegas, E. C. (2020) · Journal of Heart Health · doi:10.16966/2379-769x.154
“This polypeptide is bonded to the GLP1 receptor in the extreme C-terminal of the molecule and is proteolyzed by dipeptidyl peptidase 4, especially in the 7-8 and 24-25 positions [33].”
BackgroundAnti-diabetes Research in India: Contributions from Industrial Organizations
Pal, S., & Pal, M. (2021) · Springer eBooks · doi:10.1007/978-981-15-8002-4_8 · Cited by 1
Directed Evolution of Stabilized Peptides with Bacterial Display
Navaratna, T. A. (2020) · Deep Blue (University of Michigan)
Glucagon‐Like Peptide‐1 Receptor Activators
Wagner, M., Evers, A., Bossart, M., & Konkar, A. A. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc268
Application in medicine: obesity and satiety control
Kondrashina, A. V., Heffernan, S., O’Brien, N. M., & Giblin, L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821389-6.00005-4
Treatment with GLP-1 Receptor Agonists
Madsbad, S., & Holst, J. J. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_20 · Cited by 1
New Kid on the Block: Semaglutide
Siddhanta, S. (2022) · Bengal Physician Journal · doi:10.5005/jp-journals-10070-7079
Hert, S. G. D. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734529586.793559018
Orale semaglutide: een nieuwe en eerste orale GLP1-receptoragonist
Soubry, E., Mathieu, C., Vandistel, G., & Mertens, A. C. (2022) · Tijdschrift voor Geneeskunde · doi:10.47671/tvg.78.22.068
Current practices in drug delivery for metabolic disorders
Jain, P., Alex, T. S., Singh, M., Hassan, N., Mirza, M. A., & Iqbal, Z. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99616-7.00016-5
Ризвановна, А. М., Zhernakova, Y. V., Saidova, M. A., & Chazova, I. E. (2022) · Systemic Hypertension · doi:10.38109/2075-082x-2022-1-39-48
Wang, M., Wang, N., Zhang, H., Liu, J., Chen, X., Feng, Y., Nan, J., & Sun, B. (2022) · Research Square · doi:10.21203/rs.3.rs-2346356/v1
Stráner, P. (2018) · Eötvös Loránd Tudományegyetem · doi:10.15476/elte.2018.138
Advances in GLP-1 receptor agonists for the treatment of type 2 diabetes
Hong, S. (2023) · BIO Web of Conferences · doi:10.1051/bioconf/20236101006
Effects of Replacing a Central Glycine Residue in GLP‐1 on Receptor Affinity and Signaling Profile
Brown, K. A., & Gellman, S. H. (2023) · ChemBioChem · doi:10.1002/cbic.202300504
Selective N-terminal modification of peptides and proteins using acyl phosphatesPreprint
Pérez, L. R., King, T. A., Finnigan, W., Angelastro, A., Goundry, W. R. F., & Flitsch, S. L. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-jm6sb
Investigating Semaglutide in Adult Patients on Body Weight Compared with Other GLP-1 Drugs
Farrash, S., Aleisa, L., Alhazmi, N. Z., Almatrafi, N., Alharbi, T., Kelantan, S., Alotaibi, L., Hunaydi, W., Alnimari, S., Alqarni, N., et al. (2023) · International Journal Of Pharmaceutical Research And Allied Sciences · doi:10.51847/j9zsdr5dno
Xie, Y., He, Q., Wang, X., & Wang, J. (2024) · Authorea · doi:10.22541/au.170670903.33408087/v1
Journal of Population Therapeutics and Clinical Pharmacology
Aboshhran, A. M., Alqahtani, S. A., Alqhtani, Y. M., Alharthi, A. S., Kahl, A. H. F., & Khormi, K. M. I. (2024) · doi:10.53555//jptcp.v30i2.4746
Aboshhran, A. M., Alqahtani, S. A., alqhtani, Y. M., Alharthi, A. S., Kahl, A. F., & Khormi, K. M. I. (2023) · Journal of Population Therapeutics and Clinical Pharmacology · doi:10.53555/jptcp.v30i2.4746
Kweon, S., Lee, J. H., Yang, S.-B., Park, S. J., Subedi, L., Shim, J., Cho, S., Choi, J. U., Byun, Y., Park, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24078417
刘, 莹. (2024) · Traditional Chinese Medicine · doi:10.12677/tcm.2024.134124
GLP1R Agonists Activate Human POMC NeuronsPreprint
Mazzaferro, S., Chen, H. C., Cahn, O., Yang, A., Shepilov, D., Chen, J., Alcaino, C., Macarelli, V., Mali, I. D., Gribble, F. M., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4855485
Wu, Y., Chen, Y., Corner, T. P., Nakashima, Y., Salah, E., Li, Z., Zhang, L., Yang, L., Tumber, A., Sun, Z., et al. (2024) · Angewandte Chemie · doi:10.1002/ange.202410438
Potent and Protease Resistant Azapeptide Agonists of the GLP‐1 and GIP Receptors
Dinsmore, T. C., Liu, J., Miao, J., Ünsal, Ö., Sürmeli, D., Beinborn, M., Lin, Y., & Kumar, K. (2024) · Angewandte Chemie · doi:10.1002/ange.202410237
Sun, R., Ronxhi, J., Yang, X., Qian, M. G., & Zhang, X. (2024) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2024.116582
The Future of Alcohol Use Disorder Treatment and Research
Srivastava, A. B., & Wai, J. M. (2024) · Psychiatry update · doi:10.1007/978-3-031-73553-0_15
Development and Exploitation of RiPPs technology for Peptide Engineering
Xu, Y. (2024) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.1161821388
Catherino, W. H. (2025) · F&S Science · doi:10.1016/j.xfss.2025.01.001
The developmental trajectory of GLP-1 receptor agonists
Kou, B., & Qian, H. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27402-2.00001-2
Cui, J., Zheng, Q., Weng, Y., Zhai, X., Su, Z. C., Du, Y., Wei, X., Yu, Y., Qu, Q., & Pan, M. (2025) · Angewandte Chemie · doi:10.1002/ange.202501488
Once Weekly Insulin: The Battle of 52 versus 365
Thomas, J. J., & Mathews, N. (2025) · Open Journal of Internal Medicine · doi:10.4236/ojim.2025.152010
Lozano, F. P., Marcos, A. R., Fernández, R. C., Rodrigo, A. B., Martínez‐Hervás, S., & Ampudia‐Blasco, F. J. (2025) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2025.501574
Recent advances in the pharmacological treatment of obesity
Nam, G. E. (2025) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0058 · Cited by 1
Selective N-terminal modification of peptides and proteins using acyl phosphatesPreprint
Pérez, L. R., King, T. A., Finnigan, W., Angelastro, A., Houghton, J. W., Tate, E. W., Goundry, W. R. F., & Flitsch, S. L. (2025) · ChemRxiv · doi:10.26434/chemrxiv-2023-jm6sb-v2 · Cited by 1
Az elhízásért az evolúció lenne a felelős?
Duda, E. (2025) · Magyar Tudomány · doi:10.1556/2065.186.2025.6.9
IMPACT OF CELEBRITY STATEMENTS ON INTERNET SEARCHES ON THE USE OF SEMAGLUTIDE FOR WEIGHT LOSS
Local Health Unit of Trapani, A. T., Provenzano, S., Santangelo, O. E., & Regional Health Care and Social Agency of Lodi, A. L. (2025) · Avicenna Bulletin · doi:10.25005/2074-0581-2025-27-2-373-384
Du, Y., Liu, T., Li, H.-L., Luo, Q., Guo, X.-Y., Wang, J., Wang, X., Zhou, Y.-M., Pan, Y., Yu, L., et al. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5c00261
Peptides as a leading class therapeutic agents: future and challenges
Tzvetkov, N. T., & Atanasov, A. G. (2025) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2025.100323
Anais Congresso Nacional Sobre Obesidade e Síndrome Metabólica
do Anais, A. P. (2025) · Scire Salutis · doi:10.6008/cbpc2236-9600.2025.003.special0001
Large chemical spaces—Modeling and searching of large chemical spaces
Orsi, M., & Reymond, J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00045-5
Varra, F., Varras, M. N., Varra, V., & Theodosis‐Nobelos, P. (2025) · Current Clinical Pharmacology · doi:10.2174/0127724328392698250818071803 · Cited by 3
Unraveling the enigma of nonalcoholic fatty liver disease: From pathogenesis to therapeutic horizons
Durgadevi, R., Saravanan, G., Lavanya, R., Abirami, G., Prakash, B. S., & Vadivukkarasi, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00011-1
The Emergence of Bioactive Peptides as Anti-diabetic Agents: A Review
Prajapati, R., Singh, R. M., Singh, V., & Katrolia, A. (2025) · Current Protein and Peptide Science · doi:10.2174/0113892037386831250806112604 · Cited by 1
The SorCS2-derived macrocycle TT-P34 drives neuroprotection in animal models of neurodegeneration
Dalby, A., Ollendorff, M. K., Palmfeldt, J., Graversgaard, M., Nordestgaard, S., Bartling, C. R. O., Budolph, K., Benson, N., Roashan, E., Pedersen, S. L., et al. (2026) · Acta Neuropathologica Communications · doi:10.1186/s40478-026-02403-x
Rosa, D. M., Santos, K. N., & Cruz, J. F. (2025) · Brazilian Journal of Health Review · doi:10.34119/bjhrv8n5-251
Pavlova, M. G. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-475
Semaglutida Off-Label: Um Estudo Exploratório Sobre o Uso Irracional e Efeitos Clínicos
Imroth, S. A., Savaris, G. F., & Tizziani, T. (2025) · doi:10.22533/at.ed.342142520115
Utility of fluorinated α-amino acids in development of therapeutic peptides
Richardson, P. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2601105 · Cited by 1
“Semaglutide also showcases the Lys-34/Arg-34 switch with now a hydrophobic C-18 fatty diacid attached through a glutamate linker at Lys-26 [116].”
Jensterle, M., Ferjan, S., Battelino, T., Kovač, J., Battelino, S., Šuput, D., Vovk, A., & Janež, A. (2021) · Figshare · doi:10.6084/m9.figshare.15020783
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031555
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031567
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031546
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031564
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031558
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031549
Jensterle, M., Ferjan, S., Battelino, T., Kovač, J., Battelino, S., Šuput, D., Vovk, A., & Janež, A. (2021) · Figshare · doi:10.6084/m9.figshare.15020780
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031561
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031552
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Figshare · doi:10.6084/m9.figshare.13031570
Clark, M. (2023) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
НОВЫЕ ПОДХОДЫ К ЛЕЧЕНИЮ ОЖИРЕНИЯ
К.Т, М., & Ш.Т, З. (2025) · Multidisciplinary Journal of Science and Technology · doi:10.5281/zenodo.17707561
Lourenço, D. L. D. S. (2022) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/3f3f-0z07
Metadata
- Authors
- Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., Strauss, H. M., Gram, D. X., Knudsen, S. M., Nielsen, F. S., Thygesen, P., Reedtz-Runge, S., & Kruse, T.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Global Research, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark
- Corresponding author
- Lau, Jesper
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-09-11
- Volume
- 58
- Issue
- 18
- Pages
- 7370-7380
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2162140339
- Cited by
- 1,105
- References
- 36
- Citations by year
- 2026: 160 · 2025: 193 · 2024: 151 · 2023: 97 · 2022: 106 · 2021: 84 · 2020: 88 · 2019: 71 · 2018: 77 · 2017: 46 · 2016: 30 · 2015: 2
- FWCI
- 44.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- semaglutide, liraglutide, glucagon-like peptide-1 analogues, GLP-1 receptor, albumin binding, weekly dosing, plasma half-life, metabolic stability, fatty acid acylation, type 2 diabetes, obesity
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Animals, Cell Line, Glucagon-Like Peptides, Half-Life, Cricetinae, Humans, Injections, Subcutaneous, Male, Mice, Obese, Models, Molecular, Structure-Activity Relationship, Swine, Swine, Miniature, Rats, Sprague-Dawley, Crystallography, X-Ray, Glucagon-Like Peptide 1, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.